All In Biotech

Drug Trial Radar · NCT06855160

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

A Phase 3a, Open-Label, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Varicella Vaccine and Priorix Compared With Subcutaneous Administration of Varivax and Priorix, When Given as a First Dose to Healthy Children 12 to 15 Months of Age

Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 911 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

911

Planned (sponsor's estimate)

Start

Apr 17, 2025

Primary completion

Sep 10, 2026

Study completion Feb 2, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Mar 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 15 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection. It compares the GSK vaccines to Merck's chickenpox vaccine, administered just under the skin. Additionally, the study will evaluate the immune response and safety of giving the GSK vaccines along with other childhood vaccines through a muscle injection.

Conditions

  • Chickenpox

Interventions

  • Candidate varicella vaccineBiological

    Investigational varicella vaccine administered intramuscularly.

  • Marketed varicella vaccineBiological

    Marketed varicella vaccine administered subcutaneously.

  • MMR vaccineBiological

    MMR vaccine administered subcutaneously or intramuscularly.

  • Hepatitis A vaccineBiological

    Hepatitis A vaccine co-administered intramuscularly.

  • PCV (pneumococcal conjugate vaccine) 13Biological

    The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.

  • PCV 20Biological

    The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.

  • VaxneuvanceBiological

    The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries Vaxneuvancewill only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with seroresponse to Varicella Zoster Virus (VZV) anti- glycoprotein E (gE) Immunoglobulin (IgG)Time frame: At Day 43
  2. Geometric Mean Concentration (GMC) of anti-VZV gE IgGTime frame: At Day 43
  3. Percentage of participants with seroresponse to MMR antigensTime frame: At Day 43
  4. GMC of Anti-measles antibodiesTime frame: At Day 43
  5. GMC of Anti-mumps antibodiesTime frame: At Day 43
  6. GMC of Anti-rubella antibodiesTime frame: At Day 43

Locations

22 sites in 7 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Tucson, Arizona · Recruiting

  • GSK Investigational Site

    Huntington Park, California · Recruiting

  • GSK Investigational Site

    Sherman Oaks, California · Recruiting

  • GSK Investigational Site

    Coral Gables, Florida · Recruiting

  • GSK Investigational Site

    Miami Lakes, Florida · Recruiting

  • GSK Investigational Site

    Tampa, Florida · Recruiting

  • GSK Investigational Site

    Idaho Falls, Idaho · Recruiting

  • GSK Investigational Site

    Dayton, Ohio · Recruiting

  • GSK Investigational Site

    Houston, Texas · Recruiting

  • GSK Investigational Site

    Lewisville, Texas · Recruiting

  • GSK Investigational Site

    Mansfield, Texas · Recruiting

  • GSK Investigational Site

    Pharr, Texas · Recruiting

  • GSK Investigational Site

    Richmond, Virginia · Recruiting

  • GSK Investigational Site

    Alken, Belgium · Recruiting

  • GSK Investigational Site

    Tartu, Estonia · Recruiting

  • GSK Investigational Site

    Athens, Greece · Withdrawn

  • GSK Investigational Site

    Athens, Greece · Recruiting

  • GSK Investigational Site

    Thessaloniki, Greece · Recruiting

  • GSK Investigational Site

    Trzebnica, Poland · Recruiting

  • GSK Investigational Site

    Brasov, Romania · Recruiting

  • GSK Investigational Site

    Calarasi, Romania · Recruiting

  • GSK Investigational Site

    Chiang Mai, Thailand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.